Introduction
Epilepsy is the most common serious neurological disease. Although the majority of patients suffering from epilepsy are wellmanaged with anti-epileptic drugs (AEDs), approximately 30% of people affected by epilepsy still have recurrent seizures and are drug resistant, which can result in a progression to intractable epilepsy (IE) [1] [2] [3] [4] . Patients with intractable temporal lobe epilepsy are usually excellent candidates for epilepsy surgery, which is efficacious in up to 70% of cases [5] . IE can give rise to serious clinical problems. Therefore, there is an urgent need for more effective therapeutic strategies to address intractable epilepsy, which is mainly represented by temporal lobe epilepsy (TLE) [4] . The roles of immune processes in many central nervous system (CNS) diseases, such as CNS vasculitis, multiple sclerosis, and acute disseminated encephalomyelitis, have been widely investigated [1] [2] [3] . In recent years, an increasing body of clinical and experimental evidence has strongly supported the hypothesis that immune processes within the brain might participate in the pathophysiology of seizures and epilepsy, and some studies have reported the existence of immunological alterations in patients with epilepsy [3, [6] [7] [8] . Furthermore, immune-modulating treatments, including corticosteroids and adrenocorticotropic hormone, have been proven successful in treating specific epilepsy syndromes and epileptic encephalopathies, such as Lennox Gastaut syndrome (LGS), Landau-Kleffner syndrome (LKS) and acute symptomatic seizures complicating bacterial and viral meningitis/meningoencephalitis, that are resistant to conventional anticonvulsants and anti-epileptic drugs (AEDs), supporting the involvement of the immune system in epilepsy [9] [10] [11] . Adrenocorticotropic hormone (ACTH) and corticosteroids are also the first-line treatment options for epilepsies during early childhood in the majority of cases [12, 13] . Furthermore, the discovery that proinflammatory cytokines are produced in response to seizures in patients with TLE implies that there may be a connection between inflammation and the pathogenesis of epilepsy [14] [15] [16] . In particular, pro-inflammatory cytokines (interleukin IL-1, IL-6, and tumor necrosis factor), growth factors, and neurotrophins were increased in the hippocampi and cortices of epileptic rats. Moreover, recent studies have indicated that growth factors and cytokines can regulate the downstream events that follow seizures [17, 18] .
B cell-activating factor (BAFF), also known as B lymphocyte stimulator (BLyS), is a highly conserved member of the tumor necrosis factor superfamily of cytokines and is mainly expressed by innate immune cells, including monocytes, macrophages, dendritic cells, and other non-hematopoietic cells [19, 20] . BAFF selectively stimulates B lymphocyte proliferation and immunoglobulin production, which could consequently modulate B cell function [21] . The physiological activity of BAFF is reportedly mediated through the three following receptors: B cell-activating factor receptor (BAFFR), transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), and B cell maturation antigen (BCMA) [20, [22] [23] [24] . Among these receptors, BAFFR is the predominant BAFF receptor expressed on peripheral B cells in both humans and mice. In humans, the BAFF-BAFFR interaction is critical to support neural cell survival and is effective in T cell costimulation [20, 21, 25] . Furthermore, BAFFR can modulate B cell survival and differentiation, including activation of the nuclear factor-kappa B (NF-kB) pathway [26, 27] . Therefore, BAFF and BAFFR regulate CNS activity mainly by promoting immune and inflammatory reactions. In humans, BAFF serum levels are significantly increased in patients with systemic lupus erythematosus, Sjögren's syndrome and rheumatoid arthritis compared to those in healthy controls [3, 28, 29] . Although BAFF and BAFFR are involved in a variety of CNS inflammatory diseases, BAFF and BAFFR have not been assessed in studies of epilepsy to date.
In our present study, we investigated BAFF and BAFFR expression in the temporal neocortex of patients with TLE. In addition, BAFF and BAFFR expression levels in the hippocampi and adjacent cortices of rats in a model of TLE were investigated using real-time quantitative polymerase chain reaction (RT-qPCR), double immunofluorescence, immunohistochemistry and Western blot analyses.
Materials and methods

Human brain tissue and clinical data
Twenty-four patients undergoing surgery for medically intractable TLE and eight patients undergoing non-epilepsy-related surgery were randomly selected from our epilepsy brain bank, which includes 300 patients with intractable TLE. The study protocol complied with the guidelines for research administration involving human subjects as proposed by completely resected. Following resection, a portion of the epileptic tissue was used for the pathological examination. For comparison, we obtained 8 temporal lobe neocortex samples from patients with brain trauma who required surgery and had no seizures after the trauma, no history of epilepsy, no exposure to AEDs or other nervous system diseases. The neuropathology examinations revealed that all resected brain tissues were normal.
Rat model of chronic epilepsy
Male Sprague-Dawley rats (n = 30) weighing 180-220 g were obtained from the Experimental Animal Center of Chongqing Medical University in China. The experimental animals were randomly divided into a normal control group (n = 15) and TLE model group (n = 15). All animal procedures were approved by the Commission of Chongqing Medical University for ethics of experiments on animals and were conducted in accordance with international guidelines. We used a lithium-pilocarpine-induced rat model of clinical epilepsy to imitate the clinical pathology of TLE [30] . All rats were maintained in a controlled standard room (22 AE 2 C, 50-60% humidity and a 12-h light/12-h dark cycle) with free access to food and water. Lithium chloride (127 mg/kg, i.p., Sigma, USA) was injected 20 h prior to pilocarpine administration. The rats were pretreated with atropine methyl nitrate (1 mg/kg, i. p) 30 min prior to the first pilocarpine injection (30 mg/kg, i.p., Sigma, USA). The rats received repeated injections of pilocarpine (10 mg/kg, i.p.) every 10 min until they developed seizures. One hour after the rats developed SE, we terminated the SE convulsions using diazepam (10 mg/kg, i.p.). Control rats were treated similarly except that they were injected with normal saline instead of pilocarpine, and there were no seizures. According to Racine's standard criteria [31] , only the rats in stages 4 and 5 were considered to successfully develop SE in the acute period and were selected for further experimentation. Spontaneous recurrent seizures of the model rats over a chronic period were monitored by a video recording system (12 h/day, for 5 days), and rats with spontaneous seizures were included in the study 2 months after the onset of SE. All experimental animals were sacrificed 60 days after SE, and the hippocampus and adjacent cortex were removed for our study.
Tissue preparation
All rats were sacrificed by decapitation after an i.p. administration of chloral hydrate (350 mg/kg, Zhongshan Golden Bridge, Inc., Beijing, China) at 60 days after modeling. All brain tissues were divided into three portions; one portion was immediately stored in liquid nitrogen for Western blot (n = 4 for each group) and RT-qPCR analyses (n = 4 for each group). Another portion was fixed in 10% phosphate-buffered formalin for 24 h. All paraffin-embedded human and rat tissues were sectioned into 5-mm-thick paraffin slices, which were stored at 4 C for subsequent use in immunohistochemical analyses (n = 4 for each group). The remaining portion was fixed in 4% paraformaldehyde for 24 h, successively placed in 20% and 30% graded sucrose solutions for 24 h (per solution), sliced into 10-mm-thick sections using a freezing microtome and then stored at À20 C for double-labeled immunofluorescence analysis (n = 3 for each group).
Western blot analysis
Human temporal neocortex and rat hippocampus and adjacent cortex were homogenized. The total proteins were extracted using a total protein extraction kit (Keygen Biotech, Nanjing, China). Protein concentration was measured using an enhanced BCA Protein Assay Kit (Beyotime, Haimen, China). We used SDS-PAGE (5% spacer gel, 60 V, 40 min; 12% and 10% separating gel, 120 V, 80 min) to separate the proteins (50 mg per lane). The proteins were electrotransferred onto a polyvinylidene fluoride (PVDF) membrane at 250 mA for 60 min. To block non-specific binding, the PVDF membranes were incubated at 37 C or 1 h in 5% skim milk. Subsequently, the membranes were incubated with polyclonal rabbit anti-BAFF (1:300, Bioss, Beijing, China), polyclonal rabbit anti-BAFFR (1:300, Bioss, Beijing, China), or rabbit anti-b-actin antibody (1:3000, Proteintech, Wuhan, China) at 4 C overnight. After three washes in Tris-buffered saline with Tween-20 (TBST) for 10 min, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:3000, Proteintech, Wuhan, China) for 1 h at 37 C and then washed with TBST three times as described above. Finally, an enhanced chemiluminescence substrate (Pierce, USA) and digital scanning (Bio-Rad Laboratories) were used to observe the protein bands in a dark room. The optical densities (ODs) of the protein bands were calculated using a Fusion FX5 image analysis system (Vilber Lourmat, Marne-la-Vallée, France).
Immunohistochemistry
According to the manufacturer's protocol, brain tissue sections were deparaffinized in xylene, rehydrated in a graded series of ethanol for 5 min, and then incubated with H 2 O 2 (0.3%, 15 min). For antigen retrieval, the sections were heated in a microwave oven with 10 mmol/L sodium citrate buffer (pH 6.0) for 15 min at 92-98 C. The sections were then incubated with goat serum (Zhongshan Golden Bridge, Beijing, China) for 30 min at room temperature. The tissue sections were incubated with rabbit anti-BAFF primary antibody BAFF (1:50) or rabbit anti-BAFFR primary antibody (1:50) overnight at 4 C. The next day, the tissue sections were incubated with secondary goat anti-rabbit antibody for 30 min at 37 C and were then treated with an avidin-biotin complex (ABC) solution (Zhongshan Golden Bridge, Beijing, China) for 30 min. The sections were washed with phosphate-buffered saline (PBS) and then incubated with 3,3-diaminobenzidine (DBA) (Zhongshan Golden Bridge) for 3 min before hematoxylin was used for counterstaining. For negative controls, PBS was used instead of the primary antibodies; all other procedures were the same as those described above. An Olympus PM20 (Olympus, Osaka, Japan) automatic microscope and a TCFY-2050 (Yuancheng, Beijing, China) pathology system were used to examine the images. Five visual field images were randomly obtained from each section. Cells with buffy staining in the cytoplasm or cell membrane were considered positive for BAFF and BAFFR. Finally, we used Image-Pro plus 5.0 software (Media Cybemetrics, USA) to calculate the mean OD of each vision field and to evaluate the immunopositivity of the images.
Double-label immunofluorescence
After antigen retrieval, the tissue sections were permeabilized with 0.4% Triton X-100 for 15 min in a 37 C water bath and were then incubated with 10% goat serum (Zhongshan Golden Bridge) for 30 min at 37 C. The tissue sections were incubated with polyclonal rabbit anti-BAFF (1:100), polyclonal rabbit anti-BAFFR C. The sections were washed with PBS three times as described above and were then mounted with 50% glycerol/PBS. Finally, laser scanning confocal microscopy (Leica Microsystems Heidelberg GmbH, Germany) on an Olympus IX 70 inverted microscope (Olympus) equipped with a Fluoview FVX confocal scan head were used to detect fluorescence.
Real-time quantitative polymerase chain reaction
Total RNA was extracted from the human temporal neocortex and rat hippocampus and adjacent cortex tissues using TRIzol reagent (Takara, Japan), according to the manufacturer's instructions. RNA purity was determined by the OD260/OD280 ratio, which between 1.8 and 2.0 was considered to be of sufficient quality for reverse transcription. The total RNA was reverse transcribed into complementary DNA (cDNA) with the Applied Biosystems Veriti 1 -Well Thermal Cycler (Thermo, USA) using a PrimeScript RT reagent Kit with gDNA Eraser (Takara, Japan). The reaction conditions for reverse transcription were 37 C for 15 min and 85 C for 5 s. Primers were designed and synthesized by Takara (Japan). GAPDH (human) and b-actin (rat) were used as the internal control genes. The sequences and product sizes for each target gene are listed in Fig. 4 . cDNA was amplified with an Eppendorf Realplex Real Time System (Eppendorf Mastercycle 1 ep realplex, Germany) using SYBR 1 Premix ExTaq TM II (Takara, Japan)
according to the manufacturer's protocol. The thermal cycling conditions for RT-qPCR were as follows: initial denaturation for 30 s at 95 C, followed by 40 cycles at 95 C for 5 s, and 60 C for 30 s, 1 cycle at 95 C for 15 s, and final melting curve analysis from 65.0 to 95.0 C (increments 0.5 C for 5 s). After RT-qPCR, amplification was verified, and the relative gene expression levels were calculated using the comparative CT method [32] . Fig. 4 . The BAFF and BAFFR mRNA levels were measured by RT-qPCR, and the changes in mRNA expression in the patients with intractable TLE and TLE rats were expressed as fold changes relative to the expression in controls; GAPDH (human) and b-actin (rat) were used as internal control genes. The BAFF and BAFFR mRNA levels were up-regulated in the temporal neocortices of the patients with TLE and in the hippocampus and adjacent cortices of the TLE rats. (a) BAFF and (b) BAFFR mRNA expression in the temporal neocortices of the patients with intractable TLE. (c) BAFF and (d) BAFFR mRNA expression in the hippocampus and adjacent cortices of the TLE rats (*P < 0.05).
Statistical analysis
All data values are expressed as means AE SD. All statistical analyses were performed with the SPSS 19.0 software package. Differences between the TLE groups and the control groups in the patients and epileptic rats were analyzed using Student's t-test. We defined statistical significance as *P < 0.05. Table 1 summarizes the clinical characteristics of the subjects in this study. The average age of the patients with intractable TLE was 20.7 AE 7.38 (range 8-36 years), which included 12 males and 12 females, whereas the mean age of the control group was 26.62 AE 13.29 years (range 17-37 years), which included 4 males and 4 females. There were no significant differences in age or gender between the intractable TLE and control groups (*P < 0.05).
Results
Clinical characteristics of the patients with TLE and control patients
Localization of BAFF and BAFFR in patients with TLE and epileptic rats
Double-immunofluorescence labeling was performed on the cortices of patients with TLE and the hippocampi and cortexes of epileptic rats. BAFF and BAFFR were co-expressed in the cytomembranes and cytoplasm of neurons, as shown by coexpression with the dendritic marker MAP2 in the temporal cortices of the patients with TLE and in the brain tissues of the model rats (Figs. 1A, 2A, 3A, and 1C, 2C, 3C ). However, BAFF and BAFFR were not co-expressed in the cytomembranes and cytoplasm with the astrocyte marker GFAP (Figs. 1B, 2B, 3B, and 1D, 2D,  3D ), indicating that BAFF and BAFFR were expressed in neurons and not in astrocytes.
3.3. mRNA expression of BAFF and BAFFR in patients with intractable TLE and TLE rats RT-qPCR was performed to detect the mRNA expression of BAFF and BAFFR in the temporal neocortices of the TLE patients, and the results revealed that these mRNA levels were up-regulated compared with those of the controls (*P < 0.05) (Fig. 4A and D) . In addition, their expression was up-regulated in the hippocampus of the TLE rats and in the adjacent cortices of TLE rats (*P < 0.05) (Fig. 4B, C, E and F) .
Up-regulated BAFF and BAFFR protein expression in the temporal neocortices of patients with intractable TLE and in the hippocampi and cortices of TLE rats
Western blot analysis showed that BAFF and BAFFR protein expression levels were increased in both patients with TLE and chronic epileptic rats. We detected a band at approximately 34 kDa for the BAFF protein, a 19-kDa band for BAFFR, and a 43-kDa band for b-actin, which was used as the positive control. The protein expression levels of BAFF and BAFFR were normalized by calculating the OD ratio of BAFF or BAFFR to b-actin. There were significant differences in the average OD ratios between the TLE group and the control group based on Student's t-test statistical analysis. BAFF and BAFFR expression levels were higher in the TLE rat model group than in the control group in both the temporal neocortex (*P < 0.05) (Fig. 5G-I ) and the hippocampus (*P < 0.05) (Fig. 5D-F) . BAFF and BAFFR protein expression levels were significantly increased in the temporal neocortices of patients with TLE (*P < 0.05) (Fig. 5A-C) compared with those of the control patients. Immunohistochemistry showed strong staining for BAFF and BAFFR in the cell membranes and cytoplasm of neurons in the temporal neocortices of patients with TLE and in the hippocampal CA1 regions and cortices of epileptic rats compared with those of the controls (Figs. 6A-C, and 7A-C ) . Additionally, BAFF and BAFFR showed a granular distribution. Statistical analyses revealed that the percentages of BAFF-and BAFFR-positive cells in the temporal neocortices of patients with intractable TLE and in the hippocampi and cortices of TLE rats were significantly increased compared with those of the controls, with significant differences between the TLE groups and the control groups (*P < 0.05) (Figs. 6D-F, and 7D-F ).
Discussion
BAFF is expressed in the normal human brain at $10% of that in lymphatic tissues and is produced by astrocytes, and BAFF was localized to astrocytes close to BAFFR-expressing immune cells [33] . BAFF regulates B cell survival, and the amount of BAFF determines the size of the B cell compartment. B cells are known to be an important part of the immune reaction. Recent studies have demonstrated that BAFF and BAFFR are widely distributed in the CNS and their important significance in controlling neural cell survival in the CNS. However, the protein expression profiles of BAFF and BAFFR and their effects in TLE are still unclear.
In our study, we detected BAFF and BAFFR protein expression in the temporal neocortices of patients with TLE and in a pilocarpineinduced rat model of epilepsy. We used RT-qPCR, Western blotting and immunohistochemistry to show that BAFF and BAFFR expression levels were significantly increased in the clinical epilepsy groups compared to those in the controls. We also used immunohistochemistry and immunofluorescence to show that BAFF and BAFFR were localized at the membranes and cytoplasm of neurons in the neocortex and hippocampus. Immunofluorescence showed that BAFF and BAFFR were co-expressed with MAP2 but not with GFAP, suggesting that BAFF and BAFFR play physiological roles in neurons but not in astrocytes. These results suggested that increased BAFF and BAFFR expression might play important roles in the pathogenesis of intractable TLE. However, the detailed mechanism for this pathogenesis is still unclear.
Other studies have shown that the CNS immune system plays a role in the epileptogenic process of epilepsy, and there is a relationship between immune disorders and epileptogenesis [34] . Furthermore, evidence has shown that an inflammatory state in the epileptic brain can increase permeability of the blood-brain barrier, which leads to enhanced neuronal excitability [35, 36] . Changes in neuronal excitability are important factors in the pathogenesis of CNS diseases, especially in epilepsy. In a study of kainic acid-treated epileptic rats, which showed that the expression levels of various pro-inflammatory cytokines and autoimmune markers, such as nuclear factor-kappa B (NF-kB), cyclooxygenase-2, Toll-like receptor family members, monocyte chemoattractant protein and various complement components, are up-regulated in neurons and glial cells [37] . Astrocytes of the CNS that produce BAFF may support B cell survival in inflammatory diseases and primary B cell lymphoma. Studies have shown that BAFFR signals in part through the TRAF2 and TRAF3 E3 ligases, leading to activation of the MAP 3-kinase NIK and IkB kinase 1 (IKK1). This signaling promotes the proteolytic processing of NFkB2 (p100) into p52, an NF-kB family transcription factor that translocates into the nucleus and regulates gene expression [38] . BAFF and BAFFR interactions are critical to the survival and maturation of primary B cells and the activation of the NF-kB pathway. Therefore, BAFF and BAFFR are involved in the inflammatory and immunity reaction by regulating the maturation and differentiation of B and T cells and through the activation of the NF-kB pathway. The NF-kB pathway plays key roles in the regulation of immune and inflammatory responses, including regulating the activity of many cytokines, chemokines, and immunoreceptors [39, 40] . Additionally, NF-kB has been implicated in the neuropathological processes of seizures and epilepsy and is essential for a number of physiological CNS functions [41] . Some studies have illustrated that NF-kB is involved in seizure susceptibility, and inhibiting NF-kB activation could enhance the efficacy of AEDs [42] . Some studies have indicated that enhanced expression of the inflammatory markers IL-10 and interferon-gamma (IFN-g) can induce the up-regulation of BAFF [19] . IL-10 and IFN-g might alter the differentiation of B cells to dendritic cells by increasing BAFF release. Furthermore, IL-10 and IFN-g are common inflammatory factors in the immune response. Therefore, increased BAFF and BAFFR expression may regulate epileptic seizures by modulating the immune and inflammatory responses.
In conclusion, our study is the first to demonstrate that BAFF and BAFFR protein expression levels were increased in the brain temporal neocortex of patients with TLE and an epileptic rat model. The results of this study indicate that the up-regulation of BAFF and BAFFR expression may contribute to the pathogenesis of epilepsy by promoting immune and inflammatory responses in neurons. Thus, these novel findings provide a theoretical basis for the treatment of epilepsy and indicated that BAFF and BAFFR may represent a potential therapeutic target for AEDs. However, the exact pathophysiological mechanism of the BAFF-BAFFR signaling pathway in epileptogenesis remains unclear, and further studies should be conducted in the future.
